Kathmere Capital Management LLC Takes $291,000 Position in Stryker Co. (NYSE:SYK)

Kathmere Capital Management LLC acquired a new position in Stryker Co. (NYSE:SYK) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 809 shares of the medical technology company’s stock, valued at approximately $291,000.

Several other large investors have also recently bought and sold shares of SYK. Edgestream Partners L.P. bought a new position in shares of Stryker in the 2nd quarter valued at about $369,000. Axxcess Wealth Management LLC grew its holdings in shares of Stryker by 1.8% in the 2nd quarter. Axxcess Wealth Management LLC now owns 5,167 shares of the medical technology company’s stock valued at $1,758,000 after buying an additional 93 shares during the period. Argent Trust Co grew its stake in Stryker by 11.7% in the second quarter. Argent Trust Co now owns 6,918 shares of the medical technology company’s stock valued at $2,354,000 after acquiring an additional 722 shares during the period. Bright Financial Advisors Inc. bought a new stake in shares of Stryker during the second quarter worth $5,811,000. Finally, Ieq Capital LLC grew its holdings in shares of Stryker by 6.0% during the second quarter. Ieq Capital LLC now owns 34,960 shares of the medical technology company’s stock worth $11,895,000 after buying an additional 1,983 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on SYK. Truist Financial boosted their price target on Stryker from $380.00 to $409.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. BTIG Research boosted their price target on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. lifted their price target on shares of Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Barclays raised their price objective on Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Finally, Robert W. Baird boosted their price target on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $405.80.

Stryker Trading Up 3.4 %

SYK opened at $381.32 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The company’s 50-day moving average is $375.12 and its 200 day moving average is $358.32. The firm has a market capitalization of $145.36 billion, a PE ratio of 40.87, a P/E/G ratio of 2.51 and a beta of 0.95. Stryker Co. has a fifty-two week low of $307.23 and a fifty-two week high of $398.20.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same period in the prior year, the firm posted $2.46 EPS. Stryker’s quarterly revenue was up 11.9% compared to the same quarter last year. As a group, research analysts predict that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date is Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio (DPR) is 36.01%.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.